AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20922557 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin plus cyclophosphamide (AC)
Number of subjects: 338
Study 20922557 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus docetaxel
Number of subjects: 338
Study 20922557 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus capecitabine
Number of subjects: 338
Study 20922557 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus gemcitabine
Number of subjects: 338
Study 20922557 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-containing regimen
Number of subjects: 338
Study 20922557 — intervention group
Group type: COMPARATOR
Intervention: Non-taxane-containing regimen (AC)
Number of subjects: 338
Study 20516273 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal A (high fat)
Number of subjects: 35
Study 20516273 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal B (bulk and low fat)
Number of subjects: 35
Study 20516273 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal C (bulk and high fat)
Number of subjects: 35
Study 20516273 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal D (high fluid and low fat)
Number of subjects: 35
Study 20516273 — intervention group
Group type: COMPARATOR
Intervention: Meal E (200 ml of water)
Number of subjects: 35
Study 18822919 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention enema with compound glutamine entero‐soluble Capsule (CGC) and oral CGC (0.8 g, thrice a day)
Number of subjects: 168
Study 18822919 — intervention group
Group type: COMPARATOR
Intervention: Retention enema with glucocorticoids and metronidazole
Number of subjects: 168
Study 15907596 — intervention group
Group type: EXPERIMENTAL
Intervention: FURP-lamivudine (test formulation)
Number of subjects: 24
Study 15907596 — intervention group
Group type: COMPARATOR
Intervention: Epivir (reference formulation)
Number of subjects: 24
Study 12870818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasic patients
Number of subjects: 21
Study 12870818 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 21
Study 12870818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Aphasic and Control)
Number of subjects: 21
Study 11052308 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 41
Study 11052308 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 41
Study 8867907 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms in 1 ml saline)
Number of subjects: 20
Study 8867907 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanin (10 micrograms/kg in 100 ml saline) infusion for 60 minutes
Number of subjects: 20
Study 8867907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of galanin (10 micrograms/kg in 100 ml saline) and GHRH (100 micrograms in 1 ml saline)
Number of subjects: 20
Study 1611439 — intervention group
Group type: EXPERIMENTAL
Intervention: MF 701 (100 mg intramuscularly once a day)
Number of subjects: 324
Study 1611439 — intervention group
Group type: COMPARATOR
Intervention: UFH (5000 units subcutaneously three times daily)
Number of subjects: 324
Study 6608336 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP), 200 mg orally
Number of subjects: 26
Study 31299912 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention including an oral 20-25 min presentation in the language of participants about cervical cancer and screening.
Number of subjects: 0
Study 31299912 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized control group (neighboring areas).
Number of subjects: 0
Study 29862484 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additive exposure (xanthan gum, carrageenan, maltodextrin, soy lecithin)
Number of subjects: 138
Study 29862484 — intervention group
Group type: EXPERIMENTAL
Intervention: Total food additive exposure
Number of subjects: 138
Study 26788923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuts (+7 kcal/kg bodyweight/day for two months)
Number of subjects: 30
Study 26788923 — intervention group
Group type: COMPARATOR
Intervention: Fruit (+7 kcal/kg bodyweight/day for two months)
Number of subjects: 30
Study 26788923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 25160843 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Weight Loss Program (SBWP)
Number of subjects: 195
Study 25160843 — intervention group
Group type: COMPARATOR
Intervention: ADOPT
Number of subjects: 195
Study 25160843 — intervention group
Group type: COMPARATOR
Intervention: MAINTAIN
Number of subjects: 195
Study 22858704 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal brackets
Number of subjects: 20
Study 22858704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual brackets
Number of subjects: 20
Study 22858704 — intervention group
Group type: COMPARATOR
Intervention: Non-bonded control teeth
Number of subjects: 20
Study 20359269 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil (EPO) 3,000 mg per day
Number of subjects: 85
Study 20359269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 1,200 IU per day
Number of subjects: 85
Study 20359269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 1,200 IU per day plus EPO 3,000 mg per day
Number of subjects: 85
Study 20359269 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 85
Study 18786318 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 2 mg.kg(‐1).d(‐1) administered continuously via intravenous pump
Number of subjects: 119
Study 18786318 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 119
Study 15791626 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of labor screening test model
Number of subjects: 691
Study 15791626 — intervention group
Group type: COMPARATOR
Intervention: Duration of labor cutoff value
Number of subjects: 691
Study 14703408 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy + radiotherapy (GTRT group, n = 20) - SBN‐1 solution 1 x 10(12) VP injected intratumorally once a week for 8 weeks, radiotherapy started on the 3rd day of gene therapy, 5 fractions a week with a fraction dosage of 2 Gy and total dosage of 70 Gy
Number of subjects: 42
Study 14703408 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT group, n = 22) - the above regimen of radiotherapy conducted
Number of subjects: 42
Study 10459960 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 1670
Study 10459960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antihypertensive treatment)
Number of subjects: 1670
Study 8736647 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mM glucose perfusate
Number of subjects: 0
Study 1679154 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 20
Study 1679154 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 1679154 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment after intracranial hemorrhage (ICH)
Number of subjects: 20
Study 1679154 — intervention group
Group type: COMPARATOR
Intervention: No heparin treatment after ICH
Number of subjects: 20
Study 6385766 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 20 mg i.m.
Number of subjects: 49
Study 6385766 — intervention group
Group type: COMPARATOR
Intervention: morphine 10 mg i.m.
Number of subjects: 49
Study 31632686 — intervention group
Group type: EXPERIMENTAL
Intervention: Single antibiotic (cefprozil)
Number of subjects: 30
Study 31632686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail of three antibiotics (meropenem, gentamicin, and vancomycin)
Number of subjects: 30
Study 29269138 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 0
Study 29269138 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 0
Study 29269138 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related decline
Number of subjects: 0
Study 27565435 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4 (quadrivalent influenza vaccine)
Number of subjects: 1242
Study 27565435 — intervention group
Group type: COMPARATOR
Intervention: IIV3 (trivalent comparator)
Number of subjects: 1242
Study 27565435 — intervention group
Group type: COMPARATOR
Intervention: IIV3 (licensed Northern Hemisphere IIV3)
Number of subjects: 1242
Study 25224876 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC‐1001 (trimebutine 3‐thiocarbamoylbenzenesulfonate)
Number of subjects: 80
Study 25224876 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC‐1001 (single-dose administration)
Number of subjects: 80
Study 25224876 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC‐1001 (food effect)
Number of subjects: 80
Study 25224876 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC‐1001 (multiple ascending doses)
Number of subjects: 80
Study 25224876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19445342 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness therapy
Number of subjects: 20
Study 19445342 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 20
Study 15200937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 15200937 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11902593 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cyclophosphamide and prednisone
Number of subjects: 0
Study 11902593 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly plasma exchange, oral cyclophosphamide, and prednisone
Number of subjects: 0
Study 11902593 — intervention group
Group type: COMPARATOR
Intervention: Sham plasma exchange and placebo medications
Number of subjects: 0
Study 9295106 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (2 mg)
Number of subjects: 0
Study 9295106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7956624 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (n=12)
Number of subjects: 29
Study 7956624 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n=17)
Number of subjects: 29
Study 2885987 — intervention group
Group type: EXPERIMENTAL
Intervention: salazosulfapyridine
Number of subjects: 81
Study 2885987 — intervention group
Group type: COMPARATOR
Intervention: aurothioglucose
Number of subjects: 81
Study 31051506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction (SR)
Number of subjects: 133
Study 30247596 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant adjuvanted zoster vaccine (HZ/su), administered in 2 doses separated by 60 days
Number of subjects: 0
Study 30247596 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated zoster vaccine (ZV)
Number of subjects: 0
Study 30247596 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant adjuvanted zoster vaccine (HZ/su)
Number of subjects: 0
Study 29328644 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple eradication therapy with probiotics (Lactobacillus Rosell‐52, Lactobacillus Rosell‐11, Bifidobacterium Rosell‐1755, Saccharomyces boulardii)
Number of subjects: 167
Study 29328644 — intervention group
Group type: COMPARATOR
Intervention: Triple eradication therapy without probiotics
Number of subjects: 167
Study 29328644 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple eradication therapy with probiotics
Number of subjects: 167
Study 24788114 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Development Accounts (CDAs) offered to treatment participants, based on the Oklahoma 529 College Savings Plan
Number of subjects: 2704
Study 23158465 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manual therapy (individualized treatment of the spine)
Number of subjects: 104
Study 21456104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 300-600 mg/day
Number of subjects: 121
Study 21456104 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR (VXR) 75-225 mg/day
Number of subjects: 121
Study 21456104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 121
Study 21456104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB)
Number of subjects: 121
Study 21456104 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR (VXR)
Number of subjects: 121
Study 17998547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 252
Study 17998547 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 252
Study 17998547 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 252
Study 15310736 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (MILK)
Number of subjects: 19
Study 15310736 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte (CHO)
Number of subjects: 19
Study 15310736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MILK and CHO
Number of subjects: 19
Study 11879296 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based moderate walking exercise intervention (at least 90 minutes per week on 3 or more days)
Number of subjects: 52
Study 11879296 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study 9747065 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg transdermal nicotine patch
Number of subjects: 62
Study 9747065 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 62
Study 8155071 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Low Energy Emission Therapy (LEET)
Number of subjects: 52
Study 8155071 — intervention group
Group type: COMPARATOR
Intervention: Inactive Low Energy Emission Therapy (LEET)
Number of subjects: 52
Study 2845031 — intervention group
Group type: EXPERIMENTAL
Intervention: CVIS instructional program on therapeutic communication
Number of subjects: 75
Study 2845031 — intervention group
Group type: COMPARATOR
Intervention: Lecture discussion on therapeutic communication and a videotape (Control)
Number of subjects: 75
Study 31369676 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad-helix treatments in specialist orthodontic clinics (QHS)
Number of subjects: 135
Study 31369676 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad-helix treatments in general dentistry (QHG)
Number of subjects: 135
Study 31369676 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable expansion plate treatments in specialist orthodontic clinics (EPS)
Number of subjects: 135
Study 31369676 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable expansion plate treatments in general dentistry (EPG)
Number of subjects: 135
Study 31369676 — intervention group
Group type: COMPARATOR
Intervention: Untreated crossbite (UC)
Number of subjects: 135
Study 31369676 — intervention group
Group type: COMPARATOR
Intervention: Normal occlusion (control group)
Number of subjects: 135
Study 29567359 — intervention group
Group type: EXPERIMENTAL
Intervention: Urticaria Activity and Impact Measure (U‐AIM)
Number of subjects: 206
Study 27650732 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 0
Study 27650732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26386791 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 5695
Study 26386791 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 5695
Study 23403597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance intervention (dance classes twice weekly for 8 months, 75 minutes each class)
Number of subjects: 112
Study 23403597 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 112
Study 23403597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance intervention
Number of subjects: 112
Study 21371172 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐ProSeal™
Number of subjects: 27
Study 21371172 — intervention group
Group type: COMPARATOR
Intervention: LMA‐Classic™
Number of subjects: 27
Study 21371172 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐ProSeal™ (suboptimal position)
Number of subjects: 27
Study 21371172 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐ProSeal™ (optimal position)
Number of subjects: 27
Study 18555581 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose laden drink
Number of subjects: 0
Study 18555581 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 0
Study 17042850 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming (Bair Hugger, Augustine Medical model 500/OR)
Number of subjects: 60
Study 17042850 — intervention group
Group type: COMPARATOR
Intervention: Electric heating pad (Operatherm 202, KanMed)
Number of subjects: 60
Study 17042850 — intervention group
Group type: COMPARATOR
Intervention: Forced-air warming and Electric heating pad
Number of subjects: 60
Study 12972528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality treatment (CMT)
Number of subjects: 247
Study 12972528 — intervention group
Group type: COMPARATOR
Intervention: Subtotal lymphoid irradiation (STLI)
Number of subjects: 247
Study 10730734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (5 mg)
Number of subjects: 40
Study 10730734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (3 microg x kg(‐1) x min(‐1))
Number of subjects: 40
Study 10730734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (5 microg x kg(‐1) x min(‐1))
Number of subjects: 40
Study 10730734 — intervention group
Group type: COMPARATOR
Intervention: Control (no vasopressor)
Number of subjects: 40
Study 9197908 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of artificial light (phototherapy)
Number of subjects: 0
Study 9197908 — intervention group
Group type: COMPARATOR
Intervention: Low levels of artificial light (phototherapy)
Number of subjects: 0
Study 1443487 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anaesthetic
Number of subjects: 40
Study 1443487 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthetic
Number of subjects: 40
Study 3455945 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Rota‐dent) with instruction by a dental hygienist
Number of subjects: 40
Study 3455945 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene kit with conventional toothbrush and self-teaching manual
Number of subjects: 40
Study 30981288 — intervention group
Group type: EXPERIMENTAL
Intervention: Backboard present
Number of subjects: 101
Study 30981288 — intervention group
Group type: COMPARATOR
Intervention: No backboard
Number of subjects: 101
Study 29289901 — intervention group
Group type: EXPERIMENTAL
Intervention: CLL/SLL cases with first degree relatives with hematological cancer
Number of subjects: 560
Study 29289901 — intervention group
Group type: EXPERIMENTAL
Intervention: CLL/SLL cases who have ever worked in agriculture
Number of subjects: 560
Study 29289901 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with CLL/SLL and central obesity
Number of subjects: 560
Study 29289901 — intervention group
Group type: COMPARATOR
Intervention: Current alcohol consumption
Number of subjects: 560
Study 29289901 — intervention group
Group type: COMPARATOR
Intervention: Type II diabetes
Number of subjects: 560
Study 26914594 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week PRT
Number of subjects: 57
Study 26914594 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week PRT
Number of subjects: 57
Study 25125505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD)
Number of subjects: 54
Study 25125505 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 54
Study 22913248 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken meat from chickens given a feed with 2% rapeseed oil plus 2% linseed oil (RLO)
Number of subjects: 46
Study 22913248 — intervention group
Group type: COMPARATOR
Intervention: Chicken meat from chickens given a feed concentrate containing 4% soybean oil (SO)
Number of subjects: 46
Study 20473045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection
Number of subjects: 50
Study 20473045 — intervention group
Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF) to the suprascapular nerve
Number of subjects: 50
Study 17850530 — intervention group
Group type: EXPERIMENTAL
Intervention: 38-item paper and pencil survey assessing workforce perceptions of hospital safety culture
Number of subjects: 21496
Study 16140428 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (10 g daily for 4 weeks)
Number of subjects: 31
Study 16140428 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (500 mg daily for 4 weeks)
Number of subjects: 31
Study 11947910 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily for 8 weeks
Number of subjects: 16
Study 11947910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10447905 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 90
Study 10447905 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural hydromorphone
Number of subjects: 90
Study 10447905 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 90
Study 8563153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 3 1/2-week pain rehabilitation program
Number of subjects: 57
Study 8563153 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and gender-matched)
Number of subjects: 57
Study 2138493 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (50 mg b.d.)
Number of subjects: 25
Study 2138493 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (500 mg b.d.)
Number of subjects: 25
Study 2138493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 25
Study 27397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dimetindene maleate gel
Number of subjects: 11
Study 27397 — intervention group
Group type: COMPARATOR
Intervention: 1% d‐chlorpheniramine maleate cream
Number of subjects: 11
Study 31756632 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 74
Study 31756632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 30831331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) technologies (eg, apps, wearables)
Number of subjects: 0